5-ethyl-4-(2-methyl-3-(trifluoromethyl)benzyl)-2-morpholino[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one | 1256289-84-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-ethyl-4-(2-methyl-3-(trifluoromethyl)benzyl)-2-morpholino[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one
• 英文别名: 5-ethyl-4-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-2-(4-morpholinyl)[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one；5-Ethyl-4-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-2-morpholin-4-yl-[1,3]thiazolo[4,5-d]pyrimidin-7-one；5-ethyl-4-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-2-morpholin-4-yl-[1,3]thiazolo[4,5-d]pyrimidin-7-one
• CAS: 1256289-84-5
• 化学式: C₂₀H₂₁F₃N₄O₂S
• 分子量: 438.474
• InChiKey: KOXJQSYGFJCMKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  86.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-2-(4-morpholinyl)[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 生成 5-ethyl-4-(2-methyl-3-(trifluoromethyl)benzyl)-2-morpholino[1,3]thiazolo[4,5-d]pyrimidin-7(4H)-one
  参考文献：
  名称：

  Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors

  摘要：

  A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 Under anchorage independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.

  DOI：

  10.1021/ml300045b

文献信息

• [EN] THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE THIAZOLOPYRIMIDINONE COMME INHIBITEURS DE LA KINASE PI3
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010135504A1

  公开（公告）日：2010-11-25

  This invention relates to the use of thiazolopyrimidinone derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of thiazolopyrimidinones in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective thiazolopyrimidinones compounds for treating cancer.

  这项发明涉及噻唑吡咯嘧啶酮衍生物在调节磷脂酰肌醇3' OH激酶家族（以下简称PI3激酶）的活性或功能，特别是抑制其活性或功能方面的用途，适当地，PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适当地，本发明涉及噻唑吡咯嘧啶酮在治疗以下一种或多种疾病状态中的用途：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植物排斥和肺部损伤。更适当地，本发明涉及PI3Kβ选择性噻唑吡咯嘧啶酮化合物用于治疗癌症。
• THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS
  申请人：Lin Hong

  公开号：US20120053147A1

  公开（公告）日：2012-03-01

  This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3K}, PI3Kβ, and/or PI3Kγ.

  本发明涉及公式（I）的新化合物及其衍生物，可用于调节磷脂酰肌醇3′ OH激酶家族（以下简称PI3激酶）的活性或功能，特别是适用于PI3Kα，PI3K}，PI3Kβ和/或PI3Kγ的抑制。
• US8410095B2
  申请人：——

  公开号：US8410095B2

  公开（公告）日：2013-04-02
• Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors
  作者：Hong Lin、Mark J. Schulz、Ren Xie、Jin Zeng、Juan I. Luengo、Michael D. Squire、Rosanna Tedesco、Junya Qu、Karl Erhard、James F. Mack、Kaushik Raha、Ramona Plant、Cynthia M. Rominger、Jennifer L. Ariazi、Christian S. Sherk、Michael D. Schaber、Jeanelle McSurdy-Freed、Michael D. Spengler、Charles B. Davis、Mary Ann Hardwicke、Ralph A. Rivero

  DOI：10.1021/ml300045b

  日期：2012.7.12

  A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 Under anchorage independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.